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Abstract
Objective: To investigate if magnetic resonance spectroscopy (MRS) is the best Magnetic Resonance (MR)-based method
when compared to gradient-echo magnetic resonance imaging (MRI) for the detection and quantification of liver steatosis
in diabetic patients in the clinical practice using liver biopsy as the reference standard, and to assess the influence of
steatohepatitis and fibrosis on liver fat quantification.
Methods: Institutional approval and patient consent were obtained for this prospective study. Seventy-three patients with
type 2 diabetes (60 women and 13 men; mean age, 5469 years) underwent MRI and MRS at 3.0 T. The liver fat fraction was
calculated from triple- and multi-echo gradient-echo sequences, and MRS data. Liver specimens were obtained in all
patients. The accuracy for liver fat detection was estimated by receiver operator characteristic (ROC) analysis, and the
correlation between fat quantification by imaging and histolopathology was analyzed by Spearman’s correlation
coefficients.
Results: The prevalence of hepatic steatosis was 92%. All gradient-echo MRI and MRS findings strongly correlated with
biopsy findings (triple-echo, rho = 0.819; multi-echo, rho = 0.773; MRS, rho = 0.767). Areas under the ROC curves to detect
mild, moderate, and severe steatosis were: triple-echo sequences, 0.961, 0.975, and 0.962; multi-echo sequences, 0.878,
0.979, and 0.961; and MRS, 0.981, 0.980, and 0.954. The thresholds for mild, moderate, and severe steatosis were: triple-echo
sequences, 4.09, 9.34, and 12.34, multi-echo sequences, 7.53, 11.75, and 15.08, and MRS, 1.71, 11.69, and 14.91.
Quantification was not significantly influenced by steatohepatitis or fibrosis.
Conclusions: Liver fat quantification by MR methods strongly correlates with histopathology. Due to the wide availability
and easier post-processing, gradient-echo sequences may represent the best imaging method for the detection and
quantification of liver fat fraction in diabetic patients in the clinical practice.
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Introduction
Non-alcoholic fatty liver disease (NAFLD) affects 10–30% of the
general population across all ethnicities and age groups [1–5].
Obesity and diabetes are the primary risk factors. Worldwide, the
prevalence of obesity, diabetes, and fatty liver is rising [1,3–5].
NAFLD is a clinicopathologic syndrome with a wide spectrum of
histological abnormalities and clinical outcomes [1,2,4,6,7]. While
some patients have isolated steatosis, others have non-alcoholic
steatohepatitis (NASH), which can progress to cirrhosis, and are at
increased risk for hepatocellular carcinoma [1,2,4,6,7]. Today,
NAFLD is the third most common indication for liver transplan-
tation in the United States and is on a trajectory to become the
most common indication [8]. Therefore, early diagnosis is
important for appropriate treatments and to prevent progression.
The prevalence of NAFLD in diabetic patients is approximately
70% [9–12]. Type 2 diabetes is an important risk factor for
NAFLD and the disease follows a more aggressive course in these
patients with necroinflammation and fibrosis [13–17]. The
prevalence of NASH in diabetic patients is not well established
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[18], but has been estimated to be between 22% and 88% [11,19].
Diabetic patients commonly have comorbidities (e.g., obesity or
coronary heart disease) and may be at higher risk of complications
during liver biopsy [20]. Therefore, noninvasive methods to
diagnose NAFLD, quantify liver fat, stage disease severity, and
monitor patients over time is important.
Several imaging methods have been used in the diagnosis of
NAFLD. Ultrasonography (US) is the most common and
accurately detects moderate and severe NAFLD, but it is not
sensitive to mild steatosis [21–23]. Interobserver agreement for the
severity of NAFLD can be as low as 55% [24]. Therefore, US does
not allow precise fat liver quantification for patient follow-up.
Computed tomography (CT) is also limited for the detection of
mild steatosis and ionizing radiation prevents its use for long-term
monitoring [21–23,25]. Magnetic resonance imaging (MRI) and
magnetic resonance spectroscopy (MRS) are considered excellent
imaging methods for the noninvasive detection and quantification
of liver fat [23,26–28]. However, the accuracy of MRI and MRS
Table 1. Triple- and Multi-echo Sequences Parameters.
Triple-echo Multi-echo
TR (ms)/TE (ms) 180/2.3, 3.45, 4.6 180/1.15, 2.3, 3.45, 4.6, 5.75, 6.9, 8.05
Flip angle (degrees) 30 15
Slice thickness (mm) 6 6
Interslice gap (mm) 1 1
Matrix 1166117 1166117
Number of slices 33 33
FOV (mm) 3506350 3506350
NSA 1 1
Acquisition time (s) 43,6 43,6
Number/duration of breath holds (s) 2/21.8 2/21.8
Parallel imaging, acceleration factor SENSE, 2 SENSE, 2
TR, repetition time; FOV, field of view; NSA, number of signals averaged; SENSE, sensitivity encoding.
doi:10.1371/journal.pone.0112574.t001
Figure 1. Representative MRS data obtained from a 62-year-old woman with type 2 diabetes and moderate steatosis. T2 estimation
was done by fitting the multiecho dataset for both water and fat components considering the spectral modeling. Fat fraction was calculated as
described in details throughout the text using the T2-corrected single echo datasets (shown in detail).
doi:10.1371/journal.pone.0112574.g001
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in the detection and quantification of liver fat fraction, the
thresholds for mild, moderate and severe steatosis, and the
influence of steatohepatitis and fibrosis on the quantification of
liver fat fraction are still unknown. Therefore, the goal of this study
was to assess the diagnostic performance of triple- and multi-echo
MRI, and 1H spectroscopy in the evaluation of hepatic steatosis,
to determine the thresholds for different steatosis grades, and to
assess if steatohepatitis and/or fibrosis changes MR quantification
of liver steatosis using histologic assessment as the reference
standard.
Materials and Methods
Patients
This prospective study was approved by the Institutional Ethics
Committee of Pedro Ernesto University Hospital. Written
informed consent was obtained from all patients. Between June
2010 and February 2012, type 2 diabetic patients at the University
of the State of Rio de Janeiro, Brazil, between 18 and 70 years of
age with clinical indications for liver biopsy to evaluate NAFLD
were consecutively enrolled. In order to study a homogeneous
population with NAFLD, patients with other chronic liver diseases
were excluded, because some of them, like hepatitis C can be
associated with fatty liver and with fibrosis. Exclusion criteria
were: other possible causes of chronic liver disease (positive
serology for hepatitis B or C), history of alcoholism ($20 g of
alcohol per day), severe or decompensated cardiopulmonary
disease, renal failure (creatinine .1.5 mg/dL), coagulopathy
disorders, medication that could cause NAFLD, contraindications
to MRI (i.e., claustrophobia or metallic implants), or refusal of
liver biopsy. Criteria for withdrawal from the study included other
etiology for chronic liver disease upon liver biopsy or insufficient
biopsy material for histological analysis.
MRI and MRS
MRI and MRS were performed during the same examination
on a 3.0 T magnet (Philips Medical Systems, Eindhoven,
Netherlands) with a Quasar dual gradient system with a peak
gradient amplitude of 80 mT/m and slew rate of 200 mT/m/ms.
A whole-body transmitter coil and an sixteen-element, receive-
only, phased-array coil were used. All patients were supine.
Patients suspended respiration at the end of inspiration for breath-
hold sequences and were instructed to breathe smoothly for the
respiratory-triggered sequences. For correct positioning, coronal
localizer images were acquired at maximum inspiration and
expiration. Axial and coronal T2 images were obtained for
anatomical reference.
Gradient echo sequences
The liver fat fraction was quantified using T1-weighted, 2D
spoiled gradient-echo sequences. Low flip angles were used to
minimize T1 effects. To estimate T2* effects, three and seven
serial echoes were obtained at different echo times. Sequence
parameters are summarized in Table 1.
MRS
Single-voxel MRS data were acquired from 30630630 mm
voxels obliquely positioned by a radiologist (D.B.P. with 10 years
of experience with liver imaging) on the Couinaud segment V that
corresponded to the location of the biopsy. Localizer sequences at
maximum inspiration, maximum expiration, and during free
breathing were used to ensure the voxel was inside the liver during
the entire respiratory cycle. Care was taken to avoid liver edges,
large hepatic vessels, and the biliary tree. Water suppression was
not performed and automated shimming generated water line
widths of 40–50 Hz.
Point -resolved spectroscopy sequences (PRESS) were used for
MRS acquisition. For T2 correction, a multi-echo version was
used and 8 spectra were collected at echo times (TE) of 40, 50, 60,
70, 80, 90, 100, and 110 ms. To minimize T1 effects, the
repetition time (TR) was 2000 ms. The number of data points
collected was 1024 across a 2000 Hz spectral window and
measurements were the averages of 2 acquisitions (Figure 1). To
estimate the fat fraction, single-echo, single-voxel MRS data were
acquired using the same sequence with the following parameters: a
TR of 4000 ms, a TE of 40 ms, a spectral window of 2000 Hz, the
number of data points collected was 1024, and the number of
acquisitions was 40 (Figure 1 - detail).
Gradient echo image analysis
All MR imaging results were interpreted by one radiologist
(D.B.P. with 10 years of experience with liver imaging), who was
blinded to spectroscopic results. Analysis was performed using a
custom analysis package in Matlab (Mathworks, Natick, MA). The
radiologist manually drew a region of interest (ROI) approxi-
mately 900 mm2 in area and placed it at segment V of the liver, in
the same region where MRS measurements and biopsies were
performed (Figure 2). The fat fraction (including correction for
T2* decay and noise bias) was obtained from average ROI values
in magnitude images using a multipeak spectral model for fat
detection [29,30].
MRS analysis
MRS data were analyzed by a MR physicist (F.F.P., 5 years of
experience with MRS) who was blinded to imaging results.
Analysis used the Advanced Method for Accurate, Robust, and
Efficient Spectral (AMARES) algorithm included in jMRUI [31].
At each echo time, the water (4.7 ppm) and fat (0.5–3 ppm) peaks
were measured. Each measurable peak area was individually
corrected for T2 decay using nonlinear least-square fits to
determine their relative proton density. The relative proton
densities of the fat peaks located underneath the water peaks
were determined according to Hamilton et al. [32]. The total fat
Figure 2. Representative out-of-phase MR images from a 62
year-old woman with type 2 diabetes and moderate steatosis.
MR images obtained from breath-hold T1-weighted triple-echo spoiled
gradient-echo sequence. ROI was manually drawn at the spectroscopic
voxel location (segment V, colocalized with liver biopsy), as shown. ROI,
region of interest.
doi:10.1371/journal.pone.0112574.g002
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proton density was defined as the sum of all T2-corrected
individual fat peaks. The proton density fat fraction (PDFF) was
calculated as the ratio of the fat proton density to the sum of the fat
and water proton densities.
Liver Biopsy and Evaluation
Liver specimens were obtained from all patients. Subcostal liver
biopsies of the segment V of the liver were performed under US
guidance using a 16-gauge Menghini biopsy needle. Specimens
were 2 cm in length or longer, fixed in 10% formaldehyde
solution, and then embedded in paraffin. The sections were then
stained with hematoxylin and eosin, Masson’s trichrome, and
Perls’ Prussian blue.
All biopsy slides were examined prospectively by a pathologist
(V.L., 28 years of experience). Semiquantitative analysis of
steatosis assessed the entire liver fragment and was performed by
calculating the percentage of steatotic hepatocytes in the liver
parenchyma. Results were classified into the following 4 groups
according to the NASH Clinical Research Network (NASH-CRN)
scoring system [33]: normal, ,5%; mild, 5–33%; moderate, 33–
66%; and severe,.66%. Steatosis measurements were scored in
increments of 5% for more precise assessment. The pathologist’s
diagnosis of steatohepatitis was based on the presence of steatosis,
hepatocyte injury (ballooning), and lobular inflammation. Fibrosis
was scored from F0 to F4 [33]. The presence of siderosis was also
evaluated.
Statistical Analyses
Statistical analyses were performed in R-project (version 2.15).
Spearman statistic was used to estimate correlations. Linear
regression analyses were conducted to explore the influence of
steatohepatitis and fibrosis in liver fat measurements. For the
linear models the areas under ROC curve were estimated with the
Obuchowski’s method[34]. Areas under the ROC curves were
estimated by the trapezoidal method for mild (5–33%), moderate
(33–66%), and severe steatosis (.66%) as reference values in
biopsy evaluations. Decision thresholds were estimated for each
MR technique through the maximization of the Youden J index
on smoothed robust ROC curves. The ROC curves were
compared using a variety of methods with a two-sided test. P
values ,0.05 indicated significant differences.
Figure 3. Flowchart of patient enrollment.
doi:10.1371/journal.pone.0112574.g003
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Results
Patients
A total of 177 patients were interviewed for this study. Ninety-
seven patients were excluded: 37 had decompensated cardiopul-
monary or renal failure, 29 had hepatitis C, 20 had alcoholism, 7
had other chronic liver diseases, and 4 had coagulopathies. Thus,
80 patients underwent MRI. Five patients were subsequently
excluded: 4 refused liver biopsy and 1 had precordial pain that
precluded biopsy. Then, two patients were withdrawal: one due to
an insufficient amount of biopsied tissue and 1 for granulomatous
hepatitis upon histological analysis (Figure 3). Therefore, the final
population of the study included 73 patients (60 women [82%]
and 13 men [18%]) aged 5469 years. The mean body mass index
(BMI) was 31.4 kg/m2 (range, 23.2–42.7 kg/m2). Ninety-six
percent (70 of 73) of patients were overweight (BMI.25 kg/m2)
and 62% (45 of 73) were obese (BMI.30 kg/m2). MRI and MRS
were performed during the same session and within 3 months after
the liver biopsy. Thirty-six percent of all patients had elevated
aminotransferase levels. Detailed demographic characteristics of
the patients are included at Table 2.
Histological Analysis
Upon histology, the prevalence of steatosis (.5%) was 92% (67
patients). Mild steatosis was detected in 35 patients, moderate in
11 patients, and severe in 21 patients. Thirty-seven percent of the
patients had steatohepatitis. Fibrosis was observed in 21 (29%)
patients. The breakdown of NAFLD fibrosis scores among these
Table 2. General characteristics of the patients.
N=73
Duration of diabetes (years) 11.0768.12
ALT* 31.59620.85
AST* 24.66613.04
Alkaline Fosfatase* 143.19673.57
Gama-Glutamil transferase* 53.77641.18
Platelet* 251,616659,678
Total cholesterol* 188.46639.10
HDL* 49.28615.49
Triglycerides* 145.59669.75
Glucose* 164663.61
HbA1c levels* 8.5962.25
Macrovascular complications 5.5%
Microvascular complications 13.7%
Hypertension 75%
Metabolic Syndrome 93.2%
Hypercholesterolemia 45.1%
Statine use 43.1%
Metformine use 90.3%
Insuline use 54.8%
* Mean 6 SD.
doi:10.1371/journal.pone.0112574.t002
Figure 4. Correlations between triple- and multi-echo sequences and MR spectroscopy versus histopathology examination.
doi:10.1371/journal.pone.0112574.g004
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patients were: F1, 12 patients; F2, 6 patients; F3, 2 patients; and
F4, 1 patient. Two patients had mild siderosis.
Correlations
Figure 4 shows correlations of the triple- and multi-echo
sequences and MR spectroscopy with histopathology. Both MRI
and MRS strongly correlated with liver biopsy findings (triple-
echo: rho= 0.819, p,0.001; multi-echo: rho= 0.773, p,0.001;
MRS: rho= 0.767, p,0.001). The correlation of PDFF in mild or
moderate hepatic steatosis was found to be better than in severe
steatosis.
Diagnostic Accuracy
The capability of each MR technique to diagnose steatosis was
evaluated using histopathology for comparison. The sensitivities,
specificities, thresholds, and AUC of each MR technique for mild,
moderate, and severe steatosis are shown in figure 5. ROC curves
were compared and a significant difference was observed for mild
steatosis between multi-echo MRI and MRS (p= 0.033). Howev-
er, no significant difference between triple-echo and multi-echo
MRI (p = 0.093) or between triple-echo MRI and MRS (p= 0.42)
was observed for mild steatosis. There was also no significant
difference among the different MR methods for the ROC curves
in moderate and severe steatosis.
The median fat fraction determined by the different MR
methods for mild steatosis varies from 4.98 to 7.06, for moderate
steatosis from 10.84 to 14.27, and for severe steatosis from 18.26 to
27.75, and a progressive increase in the interquartile ranges using
the same MR method is noted with no overlap (Table 3).
Comparative analyses were performed in all groups, analyzed as
paired comparisons between two groups to find out the differences
between groups. All the comparative analyses showed p,0.05,
suggesting that all the groups are different.
One may see that the overall performance measures of the
linear models do not change much when a univariable (with
imaging only) and multivariable (with steatohepatitis and fibrosis
(F0 vs. F1–F4)) are conducted in any of the MR technique
(Table 4 and Table 5). Therefore, despite they are significant in
the model, fibrosis and steatohepatitis contribute very little to the
imaging results.
Discussion
Our study evaluated two MRI chemical shift techniques (triple-
and multi-echo imaging) and MRS to diagnose steatosis and
quantify fat in the livers of patients with type 2 diabetes. We
compared these techniques to histopathological findings. Our
results demonstrated that all MR techniques had high sensitivity
and specificity for NAFLD diagnosis and strongly correlated with
histopathology. In mild steatosis, a similar performance was
observed between triple-echo sequences and MRS. In moderate
Figure 5. Diagnostic performance for triple- and multi-echo sequences, and MRS using histopathology as the gold standard. The
best cut-off point was identified using the Youden index.
doi:10.1371/journal.pone.0112574.g005
Table 3. Triple- and Multi-echo MRI and MRS medians for no steatosis, mild, moderate, and severe steatosis using biopsy
evaluations as reference values.
No Steatosis Mild Steatosis Moderate Steatosis Severe Steatosis Total p value
6 35 11 21 73
Triple-echo
median (IQR)
2.62 (2.11,3.08) 5.08 (3.56,7.05) 12.17 (9.32,13.25) 21.75 (16.36,25.68) 8.76 (4.45,16.19) ,0.001
Multi-echo
median (IQR)
5.16 (4.77,6.24) 7.06 (5.76,10.12) 14.27 (12.28,17.41) 25.73 (19.48,30.74) 10.69 (6.48,19.14) ,0.001
MRS median
(IQR)
0.12 (0.06,0.66) 4.98 (3.12,7.05) 10.84 (10.32,14.53) 18.26 (15.28,24.9) 7.53 (3.59,15.28) ,0.001
MRI, magnetic resonance imaging; MRS, magnetic resonance spectroscopy; IQR, interquartile range;
All the groups were compared by 262 independent sample tests and the p values were ,0.05 in all the analyses.
doi:10.1371/journal.pone.0112574.t003
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and severe steatosis there was no significant difference among
triple- and multi-echo sequences and MRS.
Although steatosis measurements by MR and histology were
correlated, the actual values were different because the parameters
used to estimate liver fat are different. Pathologists quantify the
percentage of hepatocytes containing fat, whereas MR measures
the signal from fat protons. Idilman et al. [35] found that PDFF
better correlated with mild or moderate hepatic steatosis than
severe steatosis, which is consistent with our data (Figure 4). These
results suggest that hepatocytes in severe steatosis contain varied
Table 4. Univariable linear regressions analyses for each one of the imaging techniques.
Stats Estimate S.E. Lower 0.95 Upper 0.95
Triple-echo model
Triple-echo 33.829 2.256 29.33 38.327
R2 0.76 - - -
ROC AUC 0.865 0.015 - -
Multi-echo model
Multi-echo 32.891 2.291 28.322 37.46
R2 0.744 - - -
ROC AUC 0.848 0.018 - -
MRS model
MRS 33.318 2.33 28.673 37.963
R2 0.742 - - -
ROC AUC 0.845 0.019 - -
S.E., standard error; ROC, receiver operating characteristic; AUC, area under the curve; MRS, magnetic resonance spectroscopy.
doi:10.1371/journal.pone.0112574.t004
Table 5. Multivariable linear regressions analysis for each one of the imaging techniques.
Stats Effect S.E. Lower 0.95 Upper 0.95
Triple-echo model
Triple-echo 28.846 2.43 23.995 33.697
NASH= yes 12.55 4.056 4.453 20.647
fibrosis = 1 20.512 4.31 29.115 8.09
fibrosis = 2 16.376 6.004 4.391 28.361
fibrosis = 3 or 4 25.499 7.306 220.083 9.084
R2 0.841 - - -
ROC AUC 0.88 0.014 - -
Multi-echo model
Multi-echo 27.718 2.4 22.927 32.508
NASH= yes 14.533 4.076 6.398 22.668
fibrosis = 1 21.147 4.412 29.954 7.66
fibrosis = 2 15.11 6.114 2.906 27.315
fibrosis = 3 or 4 27.03 7.426 221.851 7.792
R2 0.835 - - -
ROC AUC 0.864 0.016 - -
MRS model
MRS 27.248 2.444 22.371 32.125
NASH= yes 14.645 4.173 6.316 22.975
fibrosis = 1 1.143 4.455 27.749 10.036
fibrosis = 2 13.483 6.258 0.992 25.975
fibrosis = 3 or 4 28.063 7.589 223.212 7.085
R2 0.828 - - -
ROC AUC 0.864 0.016 - -
S.E., standard error; ROC, receiver operating characteristic; AUC, area under the curve; NASH, non-alcoholic steatohepatitis; MRS, magnetic resonance spectroscopy.
doi:10.1371/journal.pone.0112574.t005
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quantities of fat, but are not distinguished from each other upon
histopathology (each is counted as a fat-containing hepatocyte).
However, MR methods quantify the amount of fat in tissue. The
fat fraction can be.2 times greater by histopathological assess-
ment than by MR techniques, suggesting that many hepatocytes
contain little fat. However, MRI and MRS measurements are
similar [36,37] to each other. Studies with larger numbers of
patients should be performed to better understand the relationship
between fat measurements by MR and histopathology.
Few studies have evaluated the influence of steatohepatitis or
fibrosis in liver fat quantification [35,38]. Although Idilman et al.
[45]. found that hepatic fibrosis reduced the correlation between
biopsy results and liver fat fraction, our results are similar to the
ones of Tang et al. [38], where the presence of steatohepatitis and/
or fibrosis did not affect MR steatosis measurements.
Our threshold values for the detection of steatosis were similar
to those in other studies that used histopathology [36,37,39–42],
but the appropriate thresholds have yet to be defined. In our study,
the threshold for the detection of mild steatosis varied from 1.71
using MRS, to 4.09 using triple-echo sequence, to 7.53 using
multi-echo MRI. Only a small overlap was observed between
patients with no steatosis vs. mild steatosis for multi-echo
sequence, where the IQR 75 for no steatosis was 6.24 and the
IQR 25 for mild steatosis was 5.76. Neither other MR method nor
other group had any overlap, suggesting that the technique may be
able to accurately differentiate the patient groups. In addition,
there were proportional increasing fat fraction medians for all MR
techniques in patients with higher steatosis grades determined by
histopathology. Thus, we believe that triple-echo, multi-echo, and
MR spectroscopy are accurate non-invasive imaging methods for
the diagnosis, grading, and follow-up of NAFLD.
Hepatic siderosis distorts the local magnetic field and causes loss
of phase coherence and T2* shortening, which leads to signal loss
at in-phase times compared to out-of-phase times [43,44]. The
T2* relaxation time varies widely among patients and using
theoretical T2* relaxation times may lead to incorrect interpre-
tations [45]. The T2* relaxation time can be calculated for each
patient using triple- and multi-echo MRI, and with T2*
correction, may prevent misinterpretation in cases of hepatic
siderosis, a condition that can be associated with NAFLD [46]. In
this study, only 2 patients had hepatic siderosis. Thus, we could
not evaluate its effects on liver fat quantification.
Gradient-echo MRI appears to be the most appropriate for
routine clinical use. In moderate and severe steatosis, no significant
difference was observed for all MR methods. In our study, triple-
echo sequence showed excellent correlation to histopathology and
was similar to MRS to detect and quantify the liver fat fraction in
mild steatosis. In addition, gradient-echo MR imaging can
measure the liver fat fraction throughout the liver, has a short
acquisition time, can be performed as a breath-hold sequence, and
does not require hardware upgrades. Furthermore, it allows
individual T2* corrections and the post-processing is easier, faster,
and less prone to misinterpretation than MRS.
Although MRS enables highly accurate liver fat quantification,
it requires strong magnetic fields, data processing is more complex
and time consuming, it requires a large team highly specialized
personnel, and is much more prone to errors. Lastly, it evaluates
only a single voxel, which can lead to misinterpretation in cases of
heterogeneous steatosis.
This study has some limitations. First, MRS was performed
using a PRESS sequence, which may be more sensitive to J
coupling effects [47]. This could lead to a systematic underesti-
mation of fat relaxation times and slightly overestimate PDFF.
Also, data acquisition time could be reduced by employing a single
signal acquisition. We averaged many MRS acquisitions to ensure
high signal-to-noise ratios and minimize baseline variations.
Therefore, MRS had to be performed during free breathing
where voxels moved 2–3 cm in the longitudinal plane. To
minimize motion-related bias, the protocol included a coronal
sequence during maximal inspiration and another during maximal
expiration to ensure voxels remained properly positioned in the
liver during acquisition. The MRI and MRS analyses were
performed only in segment V, in the location corresponding to the
liver biopsy and other liver segments were not evaluated to
maintain clinically reasonable scan times. MRS voxels could also
be difficult to position because of the biliary tree, vessels, and
magnetic susceptibility in other liver segments. The prevalence of
NAFLD in our population was extremely high and this could have
negatively influenced the specificity, but this is inherent in the
studied population. To the best of our knowledge, this is the first
study to compare fat quantification by MRI and histopathology in
diabetic patients. In addition, our study evaluated the performance
of triple- and multi-echo MRI and MRS, with individual T2* and
T2 corrections, respectively, which are important steps to allow
comparisons between different magnets at different institutions.
In summary, MR measurements may be useful to screen for
NAFLD. Liver fat quantification by MRI and MRS strongly
correlated with histopathology, even in the presence of steatohe-
patitis and fibrosis. Triple- and multi-echo MRI and MRS were
highly accurate and may be used as a substitute for liver biopsy.
Due to the wide availability and easier post-processing, gradient-
echo MRI appears to be the most appropriate for routine clinical
use in the evaluation of NAFLD in diabetic patients.
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